Improving Patient Outcomes and Evidence-based Management of NSCLC: Quality Improvement through Adherence to Clinical Guidelines and Quality Measures

Activity Details
  • Credit Type: Other
  • Credit Amount: 1.00
  • Cost: Free
  • Release: May 16, 2018
  • Expires: May 15, 2019
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

Susanne M.  Arnold Susanne M. Arnold, MD
Professor, Medical Oncology
Associate Director, Clinical Translation
Department of Oncology
Division of Internal Medicine
College of Medicine
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Goetz Kloecker Goetz Kloecker, MD, MBA, MSPH
Associate Professor
Hematology and Oncology
Director of the Thoracic Oncology Clinic Director of the Hematology/Oncology Fellowship Program
University of Louisville
Louisville, Kentucky

Needs Statement

Recent and rapid practice changing innovations in the diagnosis and management of non-small cell lung cancer create a need to disseminate information to lung cancer care clinicians

Target Audience

The target audience includes all individuals involved in the management of non-small cell lung cancer, including physicians, nurses, allied health clinicians, and other clinical staff

Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate current practice in relation to NSCLC clinical guidelines and NSCLC quality measures
  • Discuss evidence-based histologic and molecular testing options for NSCLC
  • Assess guideline-adherent treatment algorithms based on predictive biomarker testing for targeted therapy of NSCLC
  • Describe collaborative management of healthy behaviors that enhance patient outcomes and encourage self-management

Accreditation

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

Faculty Disclosure

No speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

In collaboration with University of Kentucky Markey Cancer Center (Research).

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.